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Abstract
Botulinum neurotoxins (BoNTs) cause the disease botulism, which can be lethal if untreated. 
There are seven known serotypes of BoNT, A-G, defined by their response to antisera. Many 
serotypes are distinguished into differing subtypes based on amino acid sequence and 
immunogenic properties, and some subtypes are further differentiated into toxin variants. Toxin 
characterization is important as different types of BoNT can respond differently to medical 
countermeasures for botulism, and characterization of the toxin can aid in epidemiologic and 
forensic investigations. Proteomic techniques have been established to determine the serotype, 
subtype, or toxin variant of BoNT. These techniques involve digestion of the toxin into peptides, 
tandem mass spectrometric (MS/MS) analysis of the peptides, and database searching to identify 
the BoNT protein. These techniques demonstrate the capability to detect BoNT and its neurotoxin-
associated proteins, and differentiate the toxin from other toxins which are up to 99.9% identical 
in some cases. This differentiation can be accomplished from toxins present in a complex matrix 
such as stool, food, or bacterial cultures and no DNA is required.
Introduction
Botulism is a disease caused by intoxication with any one of the highly toxic proteins known 
as botulinum neurotoxins (BoNTs). BoNT are composed of a heavy chain, which binds to 
receptors on the neuron, and a light chain which is a protease. In vivo, the BoNT light chain 
cleaves proteins necessary for nerve signal transmission resulting in flaccid paralysis. 
Botulinum neurotoxins are currently classified into seven serotypes, labeled A-G. 
BoNT/A, /C, and /E cleave SNAP-25 (synaptosomal-associated protein) [1–6] whereas 
BoNT/B, /D, /F, and /G cleave synaptobrevin-2 (also known as VAMP-2) [7–12]. BoNT/C 
is unique in that it targets more than one protein; it is also known to cleave syntaxin [13]. 
BoNT is produced as a protein complex in conjunction with neurotoxin-associated proteins 
(NAPs).
The seven different serotypes of BoNT are defined by their ability to be neutralized by an 
antiserum produced using a specific BoNT type. Therefore, identification of the serotype of 
BoNT is important as each serotype is neutralized by a different antiserum. Nucleotide or 
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amino acid sequence variation within BoNTs in strains of a serotype has led to the 
designation of subtypes. Historically, subtypes have been defined by cultural/biochemical 
characteristics [14], functional differences [15], or differential binding of monoclonal 
antibodies (mAbs) [16–18]. Amino acid variation within a subtype can vary by as much as 
30%, in the case of BoNT/F1 and /F5 [19], although amino acid variance within a serotype 
is typically less than 10%. This variation could be due to a new strain (Clostridium 
organism) or toxin variant (neurotoxin protein), with some of the neurotoxins of some 
strains having as few as a single amino acid difference, or 0.08% difference.
Identification of the subtype of BoNT is important for several reasons. First, one definition 
of a subtype of BoNT indicates that different subtypes of toxin may have differential 
binding to monoclonal antibodies, and perhaps some polyclonal antibodies [15, 20]. This is 
important while researchers search for an alternative treatment to the currently used equine 
immunoglobulin approach to treat botulism. Various mAb are proposed as immunoglobulin 
treatments for botulism; however, if there is differential binding of these antibodies to 
different subtypes, care must be taken in choosing which antibodies to use as treatment, as 
the antibodies might not be effective at neutralizing all subtypes of BoNT within a serotype. 
Secondly, identification of the BoNT subtype could be important to epidemiologic and 
forensic investigations attempting to trace the origin of the toxin, its spread in a botulism 
incident, and commonality/differences in concurrent botulism outbreaks.
Subtype identification is typically accomplished through DNA sequencing of the toxin’s 
genes [21]. Other DNA analysis techniques such as pulsed field gel electrophoresis [22], 
randomly amplified polymorphic DNA analysis [23], amplified fragment-length 
polymorphism analysis [24], flaA variable-region sequencing [25], multilocus sequence 
typing [26], multiple locus variable-number tandem repeat analysis [27], and a comparative 
genomic hybridization microarray [28] have also been used to differentiate strains. All of 
these methods depend on the presence of bacterial DNA in the sample material. However, in 
some botulism cases, BoNT is present but the bacterium cannot be isolated or cultured. In 
such a situation, toxin subtype identification or strain characterization is difficult, but 
perhaps possible, using traditional DNA-based methods [27, 29] as samples can still contain 
small amounts of DNA. In cases that no DNA is found, then the DNA-based methods cannot 
be used for subtype identification. Therefore, an alternate method which does not rely upon 
the presence of DNA may be the only option for subtype/toxin variant identification. 
Additionally, proteomic techniques are very rapid and have been used to quickly answer 
critical questions in the required time frame of a botulism outbreak investigation. In this 
review, we detail proteomic methods which yield information on the amino acid sequence of 
the toxin in question and thus reveal its serotype or subtype/toxin variant.
Mass Spectral Identification of Botulinum Neurotoxin Serotype
The seven known serotypes of BoNT are 34–64% identical to each other at the amino acid 
sequence level [30]. Because these proteins contain hundreds of amino acid differences, it is 
possible to distinguish these serotypes from each other through analysis of their amino acid 
sequences. Mass spectrometry has become a popular technique for identification of the 
amino acid sequence of a protein in question, and in 2002, van Baar et al reported on their 
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mass spectral analysis of BoNT/A and /B [31]. In this work, they digested the BoNT/A 
and /B protein complexes with trypsin, resulting in a series of peptides. The peptides were 
analyzed by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) to 
obtain a peptide mass fingerprinting (PMF) map, and in some selected cases, peptides were 
sequenced using MALDI with post-source decay (PSD). Peptides were also separated by 
liquid chromatography (LC) and then analyzed by electrospray ionization tandem mass 
spectrometry (ESI-MS/MS) on a quadrupole time-of-flight (QTOF) instrument. PMF data or 
MS/MS were then searched against the NCBI database containing BoNT protein sequences. 
Through this work, they reported a sequence coverage of greater than 35% for BoNT/A and 
25% for BoNT/B. These sequence coverages are sufficient to identify the protein as BoNT 
and to differentiate at the serotype level, as BoNT/A or /B.
In 2004, van Baar et al extended this work to encompass serotypes /C, /D, /E, and /F [32]. 
This work used the same analysis techniques as their previous report [29]. Through this 
work, they reported sequence coverages of 11% for BoNT/C, 49% for BoNT/D, 30% for 
BoNT/E, and 53% for BoNT/F. Because these proteins are 36% or more dissimilar, these 
sequence coverages were sufficient to identify the protein as BoNT and to differentiate the 
serotype of BoNT. It should be noted that there are other published, non-proteomic mass 
spectrometric methods which detect BoNT and differentiate at the serotype level [33, 34]. 
These methods detect and identify BoNT by detecting the specific enzymatic activity of the 
neurotoxin. Because each serotype of toxin has a different cleavage site on synaptobrevin-2 
or SNAP-25, mass spectrometric detection of the cleavage of synaptobrevin-2 or SNAP-25 
at that particular cleavage site will identify the presence of BoNT and differentiate the 
serotype. While these methods are good at detecting the presence of active BoNT and 
differentiating the serotype, such a method is inadequate at differentiating beyond the 
serotype levels as all BoNT subtypes within a serotype cleave synaptobrevin-2 or SNAP-25 
in the same location [35], with the exception of BoNT/F5 [7].
Mass Spectral Identification of Neurotoxin-Associated Proteins
BoNTs are produced by Clostridum botulinum, C. butyricum, C. baratii, and C. 
argentinense, and are produced as a protein complex also known as the progenitor toxin, 
consisting of the neurotoxin and neurotoxin-associated proteins (NAPs). The composition of 
the progenitor toxin can differ between serotypes. The role of these NAPs has not been 
completely deduced; however, it is likely that the NAPs serve to protect the neurotoxin from 
harsh conditions found in the stomach and digestive tract, including low pH and digestive 
enzymes [36]. Additionally, it has been proposed that these NAPs assist with translocation 
of the neurotoxin across the intestinal epithelium [37], and the NAPs may assist with the 
immunogenicity of BoNT/A [38]. Identification and characterization of the NAPs may also 
assist with BoNT serotype identification as these proteins differ between serotypes.
Mass spectral identification of the NAPs associated with BoNT/A-G was first reported in 
2005 [39]. In this work, the protein complexes of BoNT/A-G were digested with trypsin, 
and the resultant peptides were separated by LC and introduced into a QTOF for analysis in 
the MS and MS/MS modes. Using Mascot, a mass spectrometric software search engine, 
mass spectral data were searched against the NCBI database for protein identification. 
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Through this work, the neurotoxins could be identified and differentiated from each other 
with sequence coverage of 18%, 23.5%, 33.3%, 18.6%, 36.5%, 21.9%, and 16.1% for 
BoNT/A-G respectively. These sequence coverages are similar to what was previously 
reported by van Baar [31, 32]. However, this work also reported for the first time, mass 
spectral identification of the NAPs, and reported that the NAPs varied between the 
serotypes.
BoNT/A was reported in a complex with nontoxic-nonhemagglutinin and hemagglutinin 
proteins; specifically, NTNH, HA-70, HA-33, HA-17, and flagellin, with sufficient 
sequence coverage to definitely identify those proteins [39]. BoNT/B was also reported in a 
complex with NTNH, HA-70, HA-33, HA-17 and flagellin, but in all cases except HA-70, 
those NAPs have different amino acid sequences, making it possible to distinguish 
serotypes. BoNT/C combines with NTNH, HA-70, HA-33, and HA-17; BoNT/D combines 
with NTNH, HA-70, HA-33, and flagellin; BoNT/E with NTNH, ORF-X1, and NBP; 
BoNT/F with NTNH only; and BoNT/G was reported in a complex with NTNH, HA-70, 
and HA-17. In all cases, the serotype of toxin complex could be differentiated based on at 
least one of the associated proteins due to the presence of NAPs with differing amino acid 
sequences [39].
Although sequence coverage of 10–50% is sufficient to differentiate BoNT serotypes, 
increased sequence coverage assures confident differentiation. In the work previously 
described in this section [31, 32, 39], a mixture of proteins was digested and analyzed. 
Analysis of protein mixtures can often result in decreased sequence coverage for any 
individual protein. In 2011, Moura et al published on the mass spectral identification of 
BoNT/C and BoNT/D complexes [40]. In this work, they separated the components of the 
progenitor complexes by gel and then digested each gel band containing an individual 
protein. Although the same proteins were identified compared to previous work [39], 
sequence coverage of most proteins reported increased even though lower amounts of toxin 
were used for this experiment [40]. Additionally, this work also utilized a label-free mass 
spectrometric quantitation method (MSE) to report that 31% of the BoNT/C complex 
consisted of the neurotoxin whereas only 22% of the BoNT/D complex consisted of the 
neurotoxin [40].
This work also reported on a 3 minute in-solution digestion of the BoNT/C and /D 
complexes [40]. Shortening of the digestion time from a traditional overnight digestion to a 
3 minute process allows for more rapid identification of the serotype of BoNT as the 
overnight digestion step is the longest step in the process. Many of these same procedures 
were used by Terilli et al in 2011, reporting on the proteomic analysis of BoNT/G. Sequence 
coverage were reported as 66% and above for BoNT/G, NTNH, HA-70, and HA-17[41], 
allowing for easy differentiation of the serotype of toxin complex. The label-free 
quantitation method (MSE) reported a molar ratio of BoNT:NTNH:HA-70:HA-17 as 
1:1:2:1, indicating that there are two molecules of NTNH and HA-70 for every one molecule 
of BoNT and HA-17.
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BoNT Serotype Detection in Complex Matrices
BoNTs are purified and sold for research purposes either in the purified neurotoxin form or 
in the purified progenitor complex form. Additionally, the toxin can be found in bacterial 
cultures, foods, and animal/human clinical samples such as serum and stool. These matrices 
contain many abundant proteins and in most cases, the level of toxin proteins is far below 
that of the level of matrix proteins. Therefore, it is of interest to be able to detect and 
differentiate the serotype of BoNT in the presence of a complex matrix.
Klaubert et al published in 2009 on a technique to identify BoNT/A, /B, /E, and /F (the four 
serotypes which are associated with human cases of botulism) in the presence of a bacterial 
culture [42]. Because one role of the NAPs is to protect the toxin from digestive conditions, 
the bacterial culture was exposed to pepsin in pH 2, and matrix proteins were digested 
whereas the toxin complex remained intact. Peptides were then separated from proteins, and 
the proteins alone were digested with trypsin and separated by 2D nano-LC using ion 
exchange chromatography coupled with reversed phase chromatography. The peptides were 
then analyzed by nano-ESI MS/MS with data searched against the NCBI database. Although 
sequence coverage was less than 10%, toxin directly from bacterial cultures of four 
serotypes could be identified and differentiated [42].
Another approach to identify BoNT in the presence of a complex matrix has been the use of 
immunoaffinity purification of the toxin from other proteins present in the matrix. Using 
antibodies to the toxin, the toxin has been isolated from food [43–45] or bacterial culture 
[44, 46]. Through this process, both BoNT/A [43–45] and BoNT/B [44, 46] were reported to 
be detected even in the presence of complex matrices. The sequence coverage on the 
neurotoxin using this process was reported as between 65 and 98%. These high sequence 
coverage ensured identification and differentiation of these toxins. Although these 
techniques report the use of serotype-specific antibodies for toxin extraction, it should be 
noted that an antibody has been reported to bind BoNT/A, /B, /E, and /F, the four serotypes 
associated with human botulism [47] and that this antibody could be used to isolate any 
BoNT associated with human cases from its complex matrix.
Differentiation of BoNT at the Subtype/Toxin Variant Level
Differentiation of BoNT at the subtype/toxin variant level can be important for forensic or 
epidemiological reasons. Although there are many methods available to detect BoNT and 
differentiate it at the serotype level, few methods exist to differentiate the toxin below the 
serotype level, and most of these methods rely upon the presence of DNA for that 
determination. The serotypes of BoNT are 34–64% identical at the amino acid level. 
Because amino acid identity increases at the subtype level (70–97.5%) and increases even 
further at the toxin variant level (greater than 97.5%), identification of as much of the amino 
acid composition of the toxin as possible enables differentiation of the neurotoxin below the 
serotype level.
The first example of mass spectrometric detection and differentiation of BoNT below the 
serotype level was in 2005 [43]. In this work, BoNT/A1 and /A2 were spiked into milk and 
extracted with antibodies to BoNT/A. Both toxins were identified as BoNT/A through their 
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enzymatic activity upon a peptide substrate, and were then digested with trypsin and 
analyzed by LC-MS/MS. Upon searching the data against the NCBI database, the toxins 
were identified as either BoNT/A1 or /A2 with sequence coverages of 65–70% [43]. In 
2010, differentiation of BoNT/B1 and /B4 from culture supernatants was reported following 
extraction of the toxin with immunoaffinity, digestion of the extracted toxin with trypsin, 
and MS/MS analysis by MALDI-TOF [44]. Similarly, differentiation of BoNT/B1–/B5 
extracted from culture supernatants was reported in 2012 [46]. Sequence coverages of 66–
77% enabled differentiation of these five different toxins at the subtype level despite 
similarities as high as 98% in the case of BoNT/B2 and /B3 [46].
In 2012, Wang et al reported on a new technique to improve sequence coverage of BoNT 
proteins [45]. This work consisted of separation of the protein complex components by 
SDS-PAGE followed by digestion of each gel band with multiple enzymes and sequential 
in-gel digestion. Peptides from the gel band containing the neurotoxin were then separated 
by LC and analyzed by MS/MS followed by database searching. This analysis yielded 
sequence coverage of 90% and greater for all serotypes of BoNT [45]. Furthermore, this 
technique was used to identify the toxin present in a toxin-contaminated carrot juice sample 
associated with a complex botulism outbreak. The toxin was first extracted from the carrot 
juice with monoclonal antibodies to BoNT/A prior to analysis with this technique. The 
sequence coverage of the toxin was 98.6%, allowing for a determination of the toxin as 
BoNT/A1 (GeneBank accession no. ABY56330) [45]. It is important to note that this high 
level of sequence coverage allowed for determination of the toxin variant in this case as 
there are two similar toxin variants which are 99.9% and 99.6% identical to the toxin variant 
identified in this sample.
All of these proteomic methods described above relied upon matching the mass spectral data 
to sequences of proteins within a database. Forcing the data to fit a protein in the database 
can lead to inaccurate identifications of proteins if the protein in question has not yet been 
discovered and sequenced. In 2012, a method was reported to identify novel subtypes or 
toxin variants of BoNT/B which have not yet been sequenced [46]. This method relied upon 
the creation of an amino acid substitution database in which each individual amino acid 
within the sequence of BoNT/B1 was mutated to the other 19 possibilities. The MS/MS data 
were then searched against this database of possible mutations for a match to a possible 
mutation. This technique was used to analyze toxin extracted from a culture supernatant of 
BoNT/B via immunoaffinity purification and resulted in the identification of 5 novel amino 
acid differences and the identification of a new subtype of BoNT/B, BoNT/B7 [46]. DNA 
sequencing confirmed the mass spectrometry results, and when the correct amino acid 
sequence was added to the database, sequence coverage of the toxin was 68% [46].
Conclusions and Future Directions
Mass spectral analysis of botulinum neurotoxins allows for identification of the toxin at the 
serotype level as well as subtype or toxin variant level provided that the sequence coverage 
of the toxin is sufficient. These analyses can be performed by ESI or MALDI mass 
spectrometers and can encompass identification of the neurotoxin-associated proteins in 
addition to the neurotoxin. BoNTs can be identified and differentiated even in the presence 
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of a complex matrix such as food or bacterial culture, and it is now possible for de novo 
identification of novel BoNTs through mass spectrometric techniques. All of this work can 
be accomplished in the absence of DNA, and is summarized in Table 1.
Identification and differentiation of botulinum neurotoxins is a growing field, and there are 
many potential new directions. One possibility includes detection of the toxin directly from 
clinical samples, particularly stool which is the dominant diagnostic matrix for infant 
botulism. Although there are mass spectrometric methods which detect the presence of 
BoNT in stool [48], there is no published work describing the proteomics of BoNT present 
in a stool sample. Obtaining amino acid sequence on BoNT through mass spectrometry 
typically requires ng levels of toxin, and often, clinical samples contain pg or lower levels of 
toxin. Therefore, toxin is not often present in clinical samples at levels adequate for subtype 
or toxin variant differentiation, and methods which could make these determinations in the 
presence of as little as 10 pg (67 attomole) of toxin could play an important role in timely 
epidemiologic or forensic investigations.
Increased sequence coverage would allow for more confident differentiation of the subtype 
or toxin variant and would also assist in epidemiologic or forensic investigations. It is 
possible that additional amino acid sequence information and hence higher sequence 
coverage could be obtained through alternate mass spectrometric fragmentation techniques 
such as electron-transfer dissociation (ETD) or electron-capture dissociation (ECD) or 
perhaps a combination of those techniques, as both techniques are reported to yield 
increased fragmentation information on larger peptides [49, 50]. A decrease in the time 
needed to make these analyses would also be an important improvement. Other possibilities 
for improvement exist in this growing field to combat the deadly disease of botulism.
The opinions, interpretations, conclusions, and recommendations are those of the authors 
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Table 1
Summary of pertinent information from references cited in this review.
Reference Method used Sequence coverage on toxin(s) Complex matrix? NAPs?
2002 van Baar MALDI-PSD/ LC-ESI-MS/MS 35% BoNT/A; 25% BoNT/B No No
2004 van Baar MALDI-PSD/ LC-ESI-MS/MS 11% BoNT/C; 49% BoNT/D, 30% BoNT/E, 53% 
BoNT/F
No No
2005 Hines LC-ESI-MS/MS 18% BoNT/A; 23.5% BoNT/B; 33.3% BoNT/C; 
18.6% BoNT/D; 36.5% BoNT/E; 21.9% BoNT/F; 
16.1% BoNT/G
No Yes
2011 Moura LC-ESI-MS/MS 44% BoNT/C; 18.4% BoNT/DC No Yes
2011 Terilli LC-ESI-MS/MS 66% BoNT/G No Yes
2009 Klaubert LC-ESI-MS/MS 6% BoNT/B, not mentioned for BoNT/A, /E, or /F Culture supernatant Yes
2005 Kalb LC-ESI-MS/MS 65–70% BoNT/A1 and /A2 Milk No
2010 Kull MALDI-MS Not mentioned Milk, apple juice, orange 
juice, ham
No
2012 Wang Gel then LC-ESI-MS/MS 99% BoNT/A; 95% BoNT/B; 90% BoNT/C; 96% 
BoNT/D; 92% BoNT/E; 97% BoNT/F; 91% 
BoNT/G
Carrot juice No
2012 Kalb LC-ESI-MS/MS 76% BoNT/B1; 76% BoNT/B2; 66% BoNT/B3; 
75% BoNT/B4; 74% BoNT/B5
Culture supernatant No
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